Results 41 to 50 of about 1,680 (126)

Evaluation of the Burden of Bone Fractures in People Living With Haemophilia: A Registry‐Based Matched Cohort Study

Haemophilia, Volume 32, Issue 2, Page 447-452, March/April 2026.
ABSTRACT Background Bone diseases, such as low bone mineral density and osteoporosis is an emerging concern in people with haemophilia (PWH). As a consequence, PWH might experience fractures more frequently than the general population. Our primary aim was to compare the incidence of bone fractures in PWH and controls without bleeding disorders.
Federico Germini, Arun Keepanasseril, Quazi Ibrahim, Emma Iserman, Alfonso Iorio, Chatree Chai‐Adisaksopha, Davide Matino   +6 more
wiley   +1 more source

Carotid Intima‐Media Thickness as a Marker of Subclinical Atherosclerosis in Adolescents With Severe Haemophilia

Haemophilia, Volume 32, Issue 2, Page 418-424, March/April 2026.
ABSTRACT Background The clinical focus of haemophilia has expanded beyond bleeding outcomes to encompass long‐term comorbidities such as cardiovascular disease (CVD). However, it remains unclear when vascular changes begin in this population. Carotid intima‐media thickness (cIMT), a validated, non‐invasive marker of subclinical atherosclerosis, may ...
Alyson Trillo, Juanita Hunter, Audrey Ofir, Jamie Shoag, Joanna A. Davis, Fernando F. Corrales‐Medina   +5 more
wiley   +1 more source

Emicizumab [PDF]

Reactions Weekly, 2020
  +5 more sources

Efficacy of emicizumab in patients with severe haemophilia A without factor VIII inhibitors in Germany: evaluation of real-life data documented by the smart medication eDiary

Therapeutic Advances in Hematology
Background: Systematically documented data on real-world use of emicizumab, a bispecific antibody factor (F)VIII mimetic, are still lacking in people with severe haemophilia A (PwSHA).
Carmen Escuriola Ettingshausen, Wolfgang Eberl, Hermann Eichler, Ronald Fischer, Christina Hart, Katharina Holstein, Ralf Knöfler, Jürgen Kreutz, Caspar David Kühnöl, Wolfgang A. Miesbach, Christian Pfrepper, Andreas Rösch, Ulrich J. Sachs, Karolin Trautmann-Grill, Wolfgang Mondorf   +14 more
doaj   +1 more source

Acceptability and Determinants for Implementation of the EnzySystem, a Novel Near‐Patient Testing Platform for Haemophilia A

Haemophilia, Volume 32, Issue 2, Page 481-489, March/April 2026.
ABSTRACT Introduction Coagulation testing in haemophilia A is limited by the scarcity of testing facilities capable of performing relevant assays. This issue incentivized the development of the EnzySystem for haemophilia A, a near‐patient testing platform aimed to measure Factor VIII activity and thrombin generation simultaneously within 1 h from 100 ...
Aernoud P. Bavinck, Kyle Davis, Lisa van Engelshoven, Monique G. van Lier, Tanja Hamacher, Nicole M. A. Blijlevens, Amy Shapiro, Saskia E. M. Schols, Waander L. van Heerde   +8 more
wiley   +1 more source

Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention

Research and Practice in Thrombosis and Haemostasis, 2019
Essentials Acquired hemophilia A is a rare bleeding disorder often accompanied by other comorbidities. We describe emicizumab use in acquired hemophilia A complicated by acute coronary syndrome.
Kathryn E. Dane, John P. Lindsley, Michael B. Streiff, Alison R. Moliterno, Mian K. Khalid, Satish Shanbhag   +5 more
doaj   +1 more source

Reference Values for the Haemophilia Joint Health Score in Patients With Severe Haemophilia Derived From the Canadian Bleeding Disorder Registry

Haemophilia, Volume 32, Issue 2, Page 534-542, March/April 2026.
ABSTRACT Background People with haemophilia (PwH) are at increased risk of joint bleeding, often leading to haemophilic arthropathy. The Haemophilia Joint Health Score (HJHS) is widely used to evaluate joint health, but its interpretability is limited by the lack of age‐based reference values.
Khang T. Nguyen, Anthony K. C. Chan, Davide Matino, Emma Iserman, Arun Keepanasseril, Karen Strike   +5 more
wiley   +1 more source

Haemophilia A management with emicizumab: A survey of haematologists in the United States

The Journal of Haemophilia Practice, 2022
Emicizumab is a bispecific monoclonal antibody approved in the United States (US) for the treatment of people with haemophilia A (PwHA) with or without factor VIII (FVIII) inhibitors.
Patel Anisha M., Owens Wendy E., Poulos Kathleen, Raimundo Karina, Wong Gabriel, Bernard Janet, Powers Janet, Ko Richard H.   +7 more
doaj   +1 more source

Exercise Programmes for People With Haemophilia: A Scoping Review

Haemophilia, Volume 32, Issue 2, Page 381-401, March/April 2026.
ABSTRACT Background Advances in haemophilia treatment have enabled safe exercise practice as recommended by disease management guidelines, yet there is no gold‐standard protocol for optimal dose. Emerging therapies could influence exercise recommendations, highlighting the need for evidence‐based guidelines tailored to people with haemophilia to ensure
Maísa Veríssimo, Tatiana Kuhn, Janaina Ricciardi, Carolina Kosour, Mônica Veríssimo, Flávia Maia, Olga Ribeiro, Renata C. Gasparino   +7 more
wiley   +1 more source

Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)

Research and Practice in Thrombosis and Haemostasis, 2022
Background Emicizumab is a subcutaneously administered humanized, bispecific, monoclonal antibody approved for prophylaxis in people with hemophilia A. Methods HAVEN 5 (NCT03315455) is a randomized, open‐label, phase 3 study of individuals aged ≥12 years
Renchi Yang, Shujie Wang, Xuefeng Wang, Jing Sun, Ampaiwan Chuansumrit, Jianfeng Zhou, Christophe Schmitt, Wanling Hsu, Jeffrey Xu, Lindong Li, Tiffany Chang, Xielan Zhao   +11 more
doaj   +1 more source